Thus, the subgroup of ACPA-negative RA patients which achieves SDFR is characterized by higher levels of MMP-3, SAA, and CRP at the time of diagnosis and a subsequent stronger decline in these levels after DMARD initiation, supporting hypothesis 2 (Fig. 1). The gene discussed is MMP3; the disease is rheumatoid arthritis.